Coronary Artery Disease, Coronary Disease, Heart Diseases, Myocardial Ischemia
Conditions
Keywords
multivessel PCI,MIDCAB,CABG, Hybrid coronary revascularization
Brief summary
Minimally invasive revascularization of the left anterior descending artery followed by stent implantation versus percutaneous coronary intervention or coronary artery bypass in patients with multi-vessel coronary disease
Detailed description
Prospective, single-center, randomized trial, intended to compare three revascularization strategies in patients with multi-vessel coronary artery disease: 1. Hybrid approach (Minimally invasive off-pump revascularization of the left anterior descending artery (LAD) with left internal mammary artery (LIMA) bypass followed by consecutive percutaneous coronary intervention (PCI) in the rest of the arteries with drug eluting stents (DES) (Hybrid group, n=50) 2. Multi-vessel PCI with DES (MV-PCI group, n=50) 3. Coronary artery bypass graft (CABG) treatment (CABG group, n=50) PCI in Hybrid and MV-PCI group will be performed with the same 2nd generation clinically proven DES (Xience V, Xience Prime). Study objective Compare three different revascularization strategies in patients with multi-vessel coronary disease The endpoints: The primary endpoints: I. % ischemic myocardium on a 12-month follow-up scan with single photon emission computed tomography (SPECT); The secondary endpoints: I. Major adverse cardiac and cerebral events (MACCE), including (1) death, (2) non-fatal myocardial infarction (non-fatal MI), transitory ischemic attack (TIA) or stroke within 30 days, 12 months and 5-year follow-up; II. Target vessel/graft failure (for any of the target vessels in a given patient - stented or grafted) = a composite of cardiac death, MI attributable to the target vessel, or clinically-driven \[ie, not angio-driven\] Target Vessel Revascularization (TVR); III. Restenosis = angiographically-detected target lesion stenosis \>50% \[diameter stenosis\] or graft stenosis \>50%; IV. Procedural success: The treatment will be considered successful when a revascularisation in the absence of complications during the index hospitalization has been achieved; V. Procedural and post-procedural hemorrhagic complications \[ Time Frame: up to discharge from the hospital \]; VI. Recovery time \[ Time Frame: up to discharge from the hospital \];
Interventions
PROCEDUREPCI
Multi-vessel PCI with DES
PROCEDUREHybrid (MIDCAB+PCI)
Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
PROCEDURECABG
Coronary artery bypass graft (CABG) treatment
Sponsors
Russian Academy of Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Multi-vessel coronary artery disease with ≥ 70% and \<96% artery stenosis (according to QCA) 2. I-IV CCS functional class of angina 3. Asymptomatic patients with stress-test documented ischemia. 4. Patients at 1 month after acute myocardial infarction 5. Ability to perform either of revascularization methods (Hybrid, MVD-PCI, CABG). 6. Consensus on the treatment strategy between the members of the working group, including cardiologist, cardiac surgeon and interventional specialist. 7. Patients must have signed an informed consent.
Exclusion criteria
1. Pregnancy. 2. Acute coronary syndrome. 3. Previous CABG. 4. Previous stent thrombosis. 5. Severe comorbidity with high procedural risk for either of the studied strategies. 6. Severe peripheral artery disease. 7. Other serious diseases limiting life expectancy (e.g. oncology) 8. Inability for long-term follow-up. 9. Participation in other clinical trials. 10. Inability to take dual antithrombotic therapy. Angiographic
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Residual ischemia | 6 - to 18-month follow-up | ≥5% residual ischemia by single photon emission computed tomography (SPECT) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Procedural success | up to discharge from the hospital | Procedural success: The treatment will be considered successful when a complete hybrid revascularisation in the absence of complications during the index hospitalization has been achieved. |
| Procedural and post-procedural blood loss and number of transfusions | up to discharge from the hospital | dynamics of hemoglobin at admission and discharge, the number of blood transfusions (in units), classification of bleeding BARC |
| MACCE | up to 5 years | Major adverse cardiac and cerebral events (MACCE), including death,a composite of major cardiac and cerebrovascular events, i.e. the first occurrence of any of the following events: Death from any cause From cardiovascular causes From noncardiovascular causes Stroke or transitory ischemic attack (TIA) MI Hospitalization for repeat revascularization procedure, target (vessel) revascularization by means of PCI or CABG. |
| Target vessel/graft failure | 6- to 18-month follow-up | (for any of the target vessels in a given patient - stented or grafted) = a composite of cardiac death, MI attributable to the target vessel, or clinically-driven \[ie, not angio-driven\] Target Vessel Revascularization (TVR); |
| Restenosis | 6- to 18-month follow-up | angiographically-detected target lesion stenosis \>50% \[diameter stenosis\] or graft stenosis \>50%; |
| Recovery time | up to discharge from the hospital | Time Frame: from the end of the intervention up to discharge from the hospital. Total duration of hospital admission |
Countries
Russia
Outcome results
None listed